Fera Pharmaceuticals LLC

FY-2023 Revenues increased by 22% at $10.0 million compared to $8.2 million for FY-2022, a $1.8 million increase. Gross margins for FY-2023 up $3.8 million compared to FY-2022 Net loss for FY-2023 of $8.5 million compared to $8.1 million for FY-2022 Q4-2023 Revenues of $3.5 million, up 51% over Q4-2022 revenues of $2.3 million Q4-2023 EBITDA profit of $0.3 million compared to an EBITDA loss of $2.2 million for Q4-2022 Q4-2023 Net loss of $0.5 million compared to a net loss of $3 million for Q4-2022 In excess of $20 million of gross financings completed during and after fiscal year 2023, including $3.8 million of debt conversions. BOUCHERVILLE, Québec, April 30, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC. (TSXV: LSL) (the “Corporation” or “LSL Pharma”), a Canadian integrated pharmaceutical company, today reported its financial results for the year-ended December 31, 2023. “During the year, LSL Pharma has completed an important corporate milestone by listing its shares on the TSX Venture Exchange. This event represents a key catalyst that enables our Company to access the required capital to accomplish its growth objectives. During the year, we have successfully completed the relocation of our LSL Laboratory operations thus providing 300% increased capacity for the site. During the same period, we successfully completed the Health Canada certification and improvement of our Steri-Med plant, with production capacity now reaching historical highs. Both sites are well positioned to achieve record levels in 2024, as we continue to add production equipment to take advantage of market demand for our products and services,” commented Francois Roberge, President and Chief Executive Officer. Commenting on the 2023 results, Luc Mainville, Executive Vice-President and Chief Financial Officer, said, “During the year, we completed a series of financial transactions aimed at positioning LSL Pharma for growth over the coming years. By raising in excess of $20 million and eliminating $3.8 million of debts and liabilities, we are taking proactive measures to strengthen our balance sheet and improve our financial performance.” 2023 Fiscal year Financial Results Revenues have increased by 22% at $10.0 million in FY-2023 compared to $8.2 million for FY-2022. As mentioned before, revenues have been positively impacted by the sales of Erythromycin ophthalmic ointment in the US market as we took advantage of a product shortage and successfully secured (via our US partner – Fera Pharmaceuticals) a temporary license granted by the FDA to sell our Canadian labelled product to US hospitals. The license has since been extended to June 30, 2024 and consequently our revenues for the first part of FY-2024 will also be positively impacted by these non-recurrent sales. Gross margins for FY-2023 have increased by $3.8 million compared to FY-2022 at $1.6 million compared to negative margins of $2.2 million. While our margins have improved significantly between the two fiscal years, our LSL plant has only reached its normal operating level at the end of FY-2023. We expect LSL Laboratory to better contribute to the overall results in FY-2024. Similar to our revenues, our gross margins have been positively impacted in the later part of the year with sales of our Erythromycin product into the US. Adjusted Gross margins % for FY-2023 after eliminating the impact of depreciation, amortization, costs related to shut-down, plant upgrades and moving costs stood at 12%, down from 41% for FY-2022. Our adjusted gross margins for FY-2022 had been favorably impacted by a large adjustment for plant shut-down and relocation costs of $4.5 million compared to a nominal impact of $0.1 million in FY-2023. EBITDA for FY-2023, after eliminating the impact of financial expenses, depreciation and amortization was a loss of $5.5 million for FY-2023 compared to a loss of $6.1 million for the prior fiscal year, a 10% improvement. Adjusted EBITDA for FY-2023 was a $0.5 million loss compared to a gain of $1.5 million for FY-22. Again, the FY-2022 were favorably impacted by the $4.5 million adjustment for plant shut-down and relocation costs compared to a nominal impact of $0.1 million in FY-2023. Adjusted EBITDA before taking into consideration the impact of plant shut-down and relocation show a $0.6 million loss for FY-2023 compared to $3 million loss in FY-2022, a $2.4 million improvement. Net loss for the 2023 fiscal year of $8.5 million compared to a loss of $8.1 million for FY-2022. Q4-2023 Financial highlights Q4-2023 Revenues of $3.5 million, up 51% over Q4-2022 of $2.3 million, positively impacted by the sales of Erythromycin ophthalmic ointment in the US market. Q4-2023 EBITDA profit of $0.3 million compared to an EBITDA loss of $2.2 million for Q4-2022 positively impacted by the margins from incremental sales of Erythromycin ophthalmic ointment in the US market. Q4-2023 Net loss of $0.5 million compared to a net loss of $3 million for Q4-2022. Q4-2023 Business Highlights October 18, 2023 – The Corporation entered into an exclusive agreement with Fera Pharmaceuticals, to provide Erythromycin ophthalmic ointment USP (5mg/g) for the treatment of newborns in U.S. hospitals. The FDA granted Fera temporary discretion to import LSL Pharma’s one-gram ointment product for the prevention of gonococcal ophthalmia neonatorum. October 25, 2023 – The Corporation announced the signing of new orders representing $2.6 million of revenues for LSL Laboratory. November 1st, 2023 – The Corporation secured gross proceeds of $2,293,000 representing the first tranche of an unsecured convertible debentures brokered private placement (the “Offering”) through the issuance of 229,300 debenture at a price of $10 per Debenture. The net proceeds of the Offering will be used for working capital, capital expenditures, and for general corporate purposes. The Offering was led by iA Capital Markets as sole agent. The Corporation has received conditional approval to list the Debentures on the TSXV after the expiry of a 4-month hold period. The Debentures are expected to trade under the symbol LSL.DB. Each Debenture will, at the option of the holder, be convertible in its entirety into Class A shares of the capital stock of the Company (the “Class A Shares”) at any time prior to the close of business on the earlier of: (i) the last business day immediately preceding the Maturity Date, and (ii) the date fixed for redemption, at a conversion price of $0.70 per Class A Share (the “Conversion Price”), subject to adjustment in certain events. A second tranche representing gross proceeds of $995,000 closed on December 8, 2023. December 4, 2023 - The Corporation appointed Luc Mainville as Executive Vice President and Chief Financial Officer. Mr. Mainville brings 30 years of experience in the capital markets and life sciences industry. He is recognized for his financial and operational leadership having been associated with several fast-growing companies. Subsequent Events Subsequent to our fiscal year-end 2023, the Corporation completed a series of transactions aimed at strengthening its balance sheet and improved its working capital and other financial ratios. On February 2, 2024 - The Corporation borrowed $0.75 million from a company controlled by an officer at 12% interest rate, repayable on February 1, 2026. $0.271 million of this amount was converted into the first tranche of the Private Placement closed on March 7, 2024. On February 29, 2024 - The Corporation signed an amendment with a Debentures holder representing $0.1 million to extend the repayment date from March 9, 2024, to March 9, 2026. As a consideration for the extension, the interest rate for has been increased from 6% to 9.5%. March 19, 2024 – The Corporation announced the closing of a non-brokered private placements for $6.4 million representing the first closing of the $8.0 million combined financings announced on March 7, 2024 (the “Financing”). Pursuant to the Financing, the Corporation has issued 16,086,893 units (the “Units”) at a price of $0.40 per unit for aggregate gross proceeds of $6,434. Each Unit consists of one class A share of the Corporation (a “Common Share”) and one Common Share purchase warrant (a “Warrant”). Each Warrant entitles the holder, subject to adjustments in certain cases, to purchase one Common Share (a “Warrant Share”) at a price of $0.70 for a period of 36 months following the closing of the Financing. Each issued Unit, Common Share, Warrant and Warrant Share will be subject to a four month hold period under the applicable securities laws. There were no finders’ fees paid in connection with this private placement. The Financing includes $2,685 in cash proceeds, and the conversion of $3,749 of the Corporation’s debts in Units. The cash proceeds of the Financing will be used to further expand production capacity at each of the LSL Laboratory and Steri-Med Pharma plants and for general working capital purpose. The conversion of debt into Units has helped strengthen the Corporation’s balance sheet by eliminating a total of $3.8 million of debts/liabilities, as described below: Accounts payable of $1.366 million Secured debenture of $0.5 million (nominal amount) Short-term note payable of $1.16 million Long-term debt of $0.59 million April 24, 2024 – LSL Pharma Group announced the second and final tranche of its private placement financing of Units for $3,794 representing the second closing of the upsized $7.5 million non-brokered private placement announced on April 11, 2024. The second tranche follows an initial first closing of $2.7 million announced on March 19, 2024, bringing the total gross cash proceeds from the private placement to $6.5 million when combined with the previous closing. In connection with this Financing, the Corporation paid to a finder dealing at arm’s length with the Corporation, finders’ fees for a total of $30,000 in cash and issued 75,000 finders’ warrants. Each Finder’s Warrant entitles the holder to purchase one (1) Common Share at a price of $0.70 for a period of 18 months following the closing of the Financing (the “Finder’s Warrants”). Subsequent to year end, the Corporation repaid multiple debts totalling $0.29 million. On April 23, 2024, LSL Pharma announced the addition of Ms. Diane Beaudry, and Mario Paradis, as new members to its Board of Directors. Ms. Diane Beaudry is a Certified Professional Accountant and Certified Director by the Institute of Corporate Director, has extensive experience in the field of finance and boards of directors. Mario Paradis is actually the Interim CFO of EXFO Inc. Prior to this, he was Vice President and Chief Financial Officer of Neptune Wellness Solutions from 2015 to 2019. Prior to 2015, he was Vice President and Chief Financial Officer at Atrium Innovations. Financial Statements and MD&A LSL Pharma Group’s financial statements and Management’s Discussion and Analysis for the year-ended December 31, 2023 are available on SEDAR at and on the Corporation website. Grant of Options The Corporation granted an aggregate of 1,555,000 stock options (“Options”) to certain officers and directors in accordance with the Corporation’s long-term incentive compensation plan. The Options will be exercisable at an exercise price of $0.40 per Class A common share of the Corporation until April 29, 2034. All options will vest on grant. ABOUT LSL PHARMA GROUP INC. LSL Pharma is an integrated Canadian pharmaceutical company specializing in the development, manufacturing and commercialization of high-quality sterile ophthalmic pharmaceuticals, as well as natural health products in solid dosage forms. For further information, please visit the following website . Forward Looking Statements This press release contains forward-looking statements about LSL Pharma’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. CONTACT: François Roberge President and Chief Executive Officer (514) 664-7700 E-mail: Investors@groupelslpharma.com or Luc Mainville Executive Vice-President and Chief Financial Officer (514) 664-7700 ext:301 E-mail: lmainville@groupelslpharma.com

$2.7M cash investments secured including $0.4M from Insiders $3.75M of Debt converted BOUCHERVILLE, Quebec, March 19, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC. (TSXV: LSL) (the "Corporation" or "LSL Pharma"), a Canadian integrated pharmaceutical company, today announced the closing on March 18, 2024 of non-brokered private placements for $6.44 million representing the first closing of the $8.0 million combined financings announced on March 7, 2024 (the “Financing”). Pursuant to the Financing, the Corporation has issued 16,086,893 units (the “Units”) at a price of $0.40 per unit for aggregate gross proceeds of $6,434,758. Each Unit consists of one class A share of the Corporation (a “Common Share”) and one Common Share purchase warrant (a “Warrant”). Each Warrant entitles the holder, subject to adjustments in certain cases, to purchase one Common Share (a “Warrant Share”) at a price of $0.70 for a period of 36 months following the closing of the Financing. Each issued Unit, Common Share, Warrant and Warrant Share will be subject to a four month hold period under the applicable securities laws. There were no finders’ fees paid in connection with this private placement. The Financing includes $2,685,426 in cash proceeds, out of maximum gross proceeds of $3.5 million (the “Placement of Units”), and the conversion of $3,749,332 of the Corporation’s debts in Units, out of a maximum of units for debts of $4.5 million (the “Units for Debts”). The cash proceeds of the Financing will be used to further expand production capacity at each of the LSL Laboratories and Steri-Med Pharma plants and for general working capital purposes. “LSL Pharma has been experiencing significant growth since the beginning of 2024. This Financing will strengthen our balance sheet and provide additional financial flexibility to capitalize on our increased production capacity and commercial expansion into the U.S.”, said Francois Roberge, President and CEO of the Corporation. “The potential for developing first-to-market ophthalmic generic products for the Canadian and U.S. markets has never been greater as we accelerate our development and regulatory initiatives to leverage and maximize our U.S. partnership with Fera Pharmaceuticals”, added Mr. Roberge. Insiders of the Corporation (the “Insiders”) participating into the financing are acquiring a total of 875,000 Units for a subscription price of $350,000. The participation of Insiders in the Financing constitutes a "related party transaction" as defined under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Corporation is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 in respect of such Insiders participation because neither the fair market value of the Financing nor the fair market value of the consideration for the Units paid by the Insiders exceeds 25% of the Corporation's market capitalization. CAUTION REGARDING FORWARD-LOOKING STATEMENTS This press release may contain forward-looking statements as defined under applicable Canadian securities legislation. Forward-looking statements can generally be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "continue" or similar expressions. Forward-looking statements are based on a number of assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Corporation's ability to control or predict, that could cause actual results or performance to differ materially from those expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, those identified in the Corporation's filings with Canadian securities regulatory authorities, such as legislative or regulatory developments, increased competition, technological change and general economic conditions. All forward-looking statements made herein should be read in conjunction with such documents. Readers are cautioned not to place undue reliance on forward-looking statements. No assurance can be given that any of the events referred to in the forward-looking statements will transpire, and if any of them do, the actual results, performance or achievements of the Corporation may differ materially from those expressed or implied by the forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. The Corporation does not undertake to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. ABOUT LSL PHArma GROUP inc. LSL Pharma Group is an integrated Canadian pharmaceutical company specializing in the development, manufacturing and distribution of natural health products and dietary supplements in solid dosage forms, as well as high-quality sterile ophthalmic pharmaceuticals. For further information, please visit the following website . Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. CONTACT : François Roberge, President and Chief Executive Officer Telephone: (514) 664-7700 E-mail: Investors@groupelslpharma.com

Revenues of $2.5M, up 25% over the last two quarters of the year; Gross margin of 18.6%, up sharply on last year's negative gross margin of (1%); Adjusted EBITDA1 of $0.1M compared with negative adjusted EBITDA of $0.9M a year earlier; Projected sequential revenue growth for Q4-23 in excess of 40%; From early 2024, the Company will take advantage of new agreements unveiled last October for purchase orders worth up to $2.6 million per year for natural health products, bringing its current order book in excess of $6 million; Temporary authorization from the U.S. Food and Drug Administration (FDA) to export its ErythromycinPr ophthalmic ointment. BOUCHERVILLE, Quebec, Nov. 29, 2023 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC (TSXV: LSL) - LSL Pharma Group Inc. ("the Company" or "LSL Pharma Group"), a Canadian integrated pharmaceutical company, has announced its financial results for the third quarter ended September 30, 2023. The Company's MD&A and unaudited consolidated financial statements are available on SEDAR+. Unless otherwise indicated, all amounts are expressed in Canadian dollars. " LSL Pharma Group has made solid progress since the start of the year, with both subsidiaries contributing to its improved financial and operating performance," said François Roberge, President and CEO of LSL Pharma Group. "The acceleration of production at LSL Laboratories ("LSL") is progressing according to plan, following the move to new facilities in La Pocatière earlier this year. We have also completed optimization measures at the Steri-Med Pharma ("Steri-Med") plant, with a view to increase its production capacity by early 2024 to meet growing demand for our products." SELECTED FINANCIAL INFORMATION (in thousands of Canadian dollars, except per share amounts) Third quarter ended Nine months ended Sept. 30, 2023 Sept. 30, 2022 Sept. 30, 2023 Sept. 30, 2022 Revenue 2,512 2,642 6,570 5,924 Gross margin 467 (13 ) 1,546 (935 ) Adjusted EBITDA1 96 (865 ) (166 ) (3,872 ) Net loss (762 ) (1,467 ) (7,996 ) (5,045 ) Net loss per share (0.01 ) (0.02 ) (0.10 ) (0.08 ) Weighted average number of shares outstanding ('000s) 82,434 64,647 79,617 64,647 ____________________________ 1 Adjusted EBITDA is a non-IFRS measure. See the Non-IFRS financial measures section for definitions and reconciliations. THIRD-QUARTER RESULTS For the third quarter ended September 30, 2023, LSL Pharma Group recorded revenues of $2.5M, down slightly from $2.6M for the same period last year, but up 24% sequentially from $2.0M in the last two quarters of the current fiscal year. The year-over-year variation reflects the gradual resumption of LSL's activities following the transition to its new manufacturing plant, as well as an extended summer shutdown at the Steri-Med plant to improve production flow and optimize equipment and production facilities. In addition, the sequential increase largely reflects the impact of the new LSL plant, as well as the effectiveness of measures implemented in previous periods. Adjusted EBITDA, which excludes non-recurring items, amounted to $0.1M, compared with a loss of $0.9 million a year earlier. This marked improvement is mainly attributable to the increase in gross profit, which totalled $0.5M compared with a loss of $13,000 last year, and to a significant reduction of administrative expenses of over 25%. The net loss for the third quarter was $0.8M, or $0.01 per share, a 47% improvement over last year's net loss of $1.5M, or $0.02 per share. RESULTS FOR THE FIRST NINE MONTHS OF 2023 For the first nine months of 2023 fiscal year, LSL Pharma Group revenues reached $6.6M, up 11% from $5.9M for the same period last year. Gross profit amounted to $1.5M, compared with a loss of $0.9M a year earlier. Adjusted EBITDA showed a loss of $0.2M, a marked improvement over the $3.9M loss posted the previous year. Net loss totaled $8.0M, or $0.01 per share, versus a loss of $5.0M, or $0.08 per share, a year earlier. FINANCIAL SITUATION Reflecting the private placements concluded in the first quarter of the year, shareholders' equity stood at $9.8M at September 30, 2023, compared with $5.6M at the beginning of the year. Long-term debt, including the current portion, totalled $10.0M, compared with $9.3M at the beginning of the year. Working capital stood at ($8.2M), compared with ($7.0M) at December 31, 2022, while $4.9M of long-term debt is now shown as a current liability due to its maturity date. SUBSEQUENT EVENT On November 1st , 2023, the Company announced the closing of the first tranche of its brokered private placement (the "Offering") through the issuance of 229,300 convertible unsecured debentures at a price of $10 per debenture, for gross proceeds of $2,293,000 out of a total of $5,000,000 (assuming full exercise of the agent's option to increase the size of the Offering to $1,000,000). The net proceeds of the Offering will be used for working capital, capital expenditures and general corporate purposes. A second tranche of the Offering is expected to close before the end of the fourth quarter. OUTLOOK "The coming quarters look promising, as we take advantage of increased production capacity at each of our subsidiary. Starting with the fourth quarter of 2023 and into 2024, we'll be taking advantage of the new agreements unveiled last October. Initially, Steri-Med will supply sterile ophthalmic ointment for the treatment of newborns in US hospitals under an exclusive agreement with US specialty pharmaceutical company Fera Pharmaceuticals, LLC. In addition, LSL will begin deliveries against new purchase orders for natural health products, the value of which could exceed $2.6M on an annual basis. Finally, we are pursuing our efforts to make strategic acquisitions that will enable us to further expand our product range and customer base," concluded Mr. Roberge. NON-IFRS FINANCIAL MEASURES The non-IFRS financial measures included in this press release are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS; they may therefore not be comparable to similar measures presented by other issuers. When used, these measures are defined so as to permit reconciliation with the most comparable IFRS measure. These measures are provided as supplementary information to complement IFRS measures, by providing a better understanding of the Company's operating results, from its perspective. Accordingly, they should not be considered in isolation, nor as a substitute for analysis of the LSL Pharma Group's IFRS financial information. Despite the importance of these measures to management in setting objectives and assessing performance, the Company emphasizes that they are non-IFRS measures whose usefulness to investors may be limited. The Company uses non-IFRS measures, such as EBITDA and Adjusted EBITDA, to provide investors with an additional measure of its operating performance and thus highlight trends in its core business that might not otherwise be apparent if only IFRS financial measures were used. The Company also notes that financial analysts, investors and other interested parties frequently use non-IFRS measures in assessing issuers. LSL Group Pharma also uses non-IFRS measures to facilitate period-to-period comparisons of operating performance, to prepare annual operating budgets, and to assess its ability to meet future debt servicing, capital expenditure and working capital requirements. The definition and reconciliation of EBITDA and Adjusted EBITDA used and presented by the Company with the most directly comparable IFRS measures are detailed below. EBITDA is defined as net income or loss adjusted for income tax expense, depreciation of property, plant and equipment, amortization of intangible assets, interest on short-term and long-term debt, and other financing costs such as foreign exchange gains or losses, interest income and other. Management uses EBITDA to assess the Company's operating performance. Adjusted EBITDA is defined as EBITDA adjusted for special employee recruitment and severance costs, special professional fees, stock-based compensation and other costs of issuing warrants or options, moving expenses and other expenses related to the Company's listing on the TSX Venture Exchange. The Company uses Adjusted EBITDA as a key measure of business performance when comparing results to budgets, forecasts and prior years. Management believes that Adjusted EBITDA is a more accurate measure of cash flow generation than, for example, cash flow from operations, as it eliminates cash flow fluctuations caused by unusual changes in working capital. Reconciliation of net loss to EBITDA and adjusted EBITDA (in thousands of Canadian dollars)* Third quarter ended Nine months ended Sept. 30, 2023 Sept. 30, 2022 Sept. 30, 2023 Sept. 30, 2022 Net loss (762 ) (1,467 ) (7,996 ) (5,045 ) Net financial expenses 426 341 1 269 408 Amortization 347 249 885 750 EBITDA 11 (877 ) (5,842 ) (3,887 ) Cost of reverse takeover - - 2,488 - Moving expenses 1 - 133 - Stock-based compensation expenses Recruitment and severance costs - 84 - 12 2,971 84 - - Adjusted EBITDA 96 (865 ) (166 ) (3,887 ) * Some calculation discrepancies are due to rounding. CAUTION REGARDING FORWARD-LOOKING STATEMENTS This press release may contain forward-looking statements as defined under applicable Canadian securities legislation. Forward-looking statements can generally be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "continue" or similar expressions. Forward-looking statements are based on a number of assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's ability to control or predict, that could cause actual results or performance to differ materially from those expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, those identified in the Company's filings with Canadian securities regulatory authorities, such as legislative or regulatory developments, increased competition, technological change and general economic conditions. All forward-looking statements made herein should be read in conjunction with such documents. Readers are cautioned not to place undue reliance on forward-looking statements. No assurance can be given that any of the events referred to in the forward-looking statements will transpire, and if any of them do, the actual results, performance or achievements of the Company may differ materially from those expressed or implied by the forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. The Company does not undertake to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. ABOUT LSL PHARMA INC. LSL Pharma Group is an integrated Canadian pharmaceutical company specializing in the development, manufacture and distribution of high-quality natural health products and dietary supplements in solid dosage forms, as well as high-quality sterile ophthalmic pharmaceuticals. For further information, please visit the following websites , and . Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. CONTACT : François Roberge, President and CEO Telephone: 514 664-7700 E-mail: Investors@groupelslpharma.com